Cargando…

MRD negativity: considerations for older adults with multiple myeloma

Detalles Bibliográficos
Autores principales:	Mian, Hira, Wildes, Tanya M., Venner, Christopher P., Fonseca, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632351/ https://www.ncbi.nlm.nih.gov/pubmed/37938551 http://dx.doi.org/10.1038/s41408-023-00939-y

Ejemplares similares

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study
por: Mian, Hira, et al.
Publicado: (2023)

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
por: Mian, Hira, et al.
Publicado: (2020)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study
por: Mian, Hira, et al.
Publicado: (2022)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
por: Mian, Hira, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study
por: Mian, Hira S., et al.
Publicado: (2020)

Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
por: Schoenbeck, Kelly L, et al.
Publicado: (2020)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

High dose therapy and autologous stem cell transplant in older adults with multiple myeloma
por: Wildes, Tanya M, et al.
Publicado: (2015)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Lifestyle considerations in multiple myeloma
por: Shapiro, Yael N., et al.
Publicado: (2021)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Mandibular Repositioning Device (MRD) and Obstructive Sleep Apnea Syndrome
por: Nicolaou, Zoe
Publicado: (2019)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
por: Mian, Hira, et al.
Publicado: (2022)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

Clinical Considerations for Immunoparesis in Multiple Myeloma
por: Chahin, Michael, et al.
Publicado: (2022)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS
por: Meseguer Martinez, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t25e9bnt9jk2jpg7jv697l12bt